Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (31)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Judson, I.
Right arrow Articles by Hanauske, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Judson, I.
Right arrow Articles by Hanauske, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 8:604-606, 1997
© 1997 European Society for Medical Oncology

other

Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: An EORTC early clinical studies group investigation

I. Judson1,, T. Cerny2, R. Epelbaum3, D. Dunlop4, J. Smyth5, B. Schaefer6, M. Roelvink6, S. Kaplan7 and A. Hanauske8

1Royal Marsden NHS Trust London, UK
2Inselspital Berne, Switzerland
3Rambam Medical Center Haifa, Israel
4Beatson Oncology Centre Glasgow, UK
5Western General Hospital Edinburgh, UK
6New Drug Development Office Amsterdam, the Netherlands
7Kantonspital Basel, Switzerland
8Technical University Munich, Germany

Correspondence to: Dr. Ian Judson CRC Centre for Cancer Therapeutics The Institute of Cancer Research 15, Cotswold Road Sutton, Surrey, SM2 5NG UK

BACKGROUND: JM216 is a new oral platinum complex with dose-limiting toxicity myelosuppresssion, now undergoing phase II evaluation.

PATIENTS AND METHODS: JM216 was evaluated as first line therapy in non-small-cell lung cancer. Seventeen patients received 120 mg/m2/day for five days repeated every three weeks.

RESULTS: Toxicity was manageable, the commonest side-effects being nausea, vomiting, diarrhoea, constipation and asthenia. Myelososuppression was generally grade <2 and there were no cases of neutropenic sepsis or bleeding. Thirteen patients were fully evaluable for response. No sustained objective responses were reported. One patient was reported as stable disease had a partial response after three courses but was progressing again after four. An additional five patients had stable disease (46.2%).

CONCLUSIONS: Although some patients may have had useful palliation, JM216 did not appear to have significant antitumour activity in non-small-cell lung cancer.

JM216, lung cancer, non-small cell, oral chemotherapy, platinum


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. D. Ricart, J. Sarantopoulos, E. Calvo, Q. S. Chu, D. Greene, F. E. Nathan, M. E. Petrone, A. W. Tolcher, and K. P. Papadopoulos
Satraplatin, an Oral Platinum, Administered on a Five-day Every-Five-Week Schedule: a Pharmacokinetic and Food Effect Study
Clin. Cancer Res., June 1, 2009; 15(11): 3866 - 3871.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Choy, C. Park, and M. Yao
Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue
Clin. Cancer Res., March 15, 2008; 14(6): 1633 - 1638.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
J. M. Perez, L. R. Kelland, E. I. Montero, F. E. Boxall, M. A. Fuertes, C. Alonso, and C. Navarro-Ranninger
Antitumor and Cellular Pharmacological Properties of a Novel Platinum(IV) Complex: trans-[PtCl2(OH)2(Dimethylamine) (Isopropylamine)]
Mol. Pharmacol., April 1, 2003; 63(4): 933 - 944.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.